Protera Appoints Novozymes Executive Thomas Videbaek As Chair of the Board of Directors and Non-Executive Board Member

April 6, 2021 2:00 AM

SANTIAGO, CHILE and PARIS, FRANCE / ACCESSWIRE / April 6, 2021 / Protera, an AI-driven startup designing and developing new proteins to enable a wide range of natural and sustainable solutions, announced today it has appointed Novozymes senior executive Thomas Videbaek as Chair of the Board of Directors and non-executive board member. Dr. Videbaek has spent the last 13 years on the executive team at Novozymes, the world leader in...

Read more

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients

April 6, 2021 1:00 AM

First Study of Ensovibep in Patients With Symptomatic COVID-19 Disease Designed To Evaluate Dynamics of Viral Clearance, Pharmacokinetics and Tolerability of Ensovibep Ensovibep Is Additionally Planned To Be Tested in Two Global, Placebo Controlled, Double Blinded Trials: A Phase 2–3 Trial in an Ambulatory Patient Setting (Named EMPATHY), and a Phase 3 Trial in a Hospitalized Patient Setting Sponsored by the NIH...

Read more

Applied UV, Inc. Appoints Mike Riccio as Chief Financial Officer

April 5, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / April 5, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that Mike Riccio, CPA, is appointed Chief Financial...

Read more

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

April 5, 2021 7:30 AM

IRVINE, CA / ACCESSWIRE / April 5, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin the U.S. pivotal trial for the VenoValve®. The VenoValve is an implantable valve designed to restore proper directional blood...

Read more

FDA Provides Positive Feedback on Tetra Bio-Pharma's Application for ARDS-003 Clinical Development in COVID-19 Patients

April 5, 2021 2:00 AM

FDA acknowledged that the preclinical safety data are acceptable to file an Investigational New Drug Application (IND) aimed at treating hospitalized COVID-19 patients at risk of developing ARDS OTTAWA, ON / ACCESSWIRE / April 5, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development is pleased to announce...

Read more

Vitro Biopharma Retains Leading Health Care Executive as Acting Director of Regulatory Affairs & Director

April 3, 2021 1:20 PM

GOLDEN, CO / ACCESSWIRE / April 3, 2021 / Vitro Biopharma, Inc. (formerly Vitro Diagnostics, Inc.) announced the appointment of Dr. Caroline Mosessian, PhD, DRSc, FACMPE, ACHE as its acting Director of Regulatory Affairs. Dr. Mosessian has an extensive background in regulatory science including a PhD, MS and Masters in Healthcare Administration degrees from USC in LA. In 2016 she was honored with the prestigious Top Ranked US Executive Award...

Read more

ProCell Surgical Inc. Awarded Breakthrough Technology Agreement With Premier

April 1, 2021 5:00 AM

CANTON, MA / ACCESSWIRE / April 1, 2021 / ProCell Surgical Inc. has been awarded a group purchasing agreement for Breakthrough Technology with Premier. Effective April 1, 2021, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Perfusion Products. "ProCell Surgical is delighted to have received a Breakthrough Technology Agreement with Premier for our...

Read more

Tetra Bio-Pharma Receives Second Compliant Rating on Inspection from Health Canada

April 1, 2021 2:00 AM

Tetra Bio-Pharma Inc. receives a Notice of Compliant rated inspection to distribute pharmaceuticals Key milestone in the development path to commercialization of Reduvo OTTAWA, ON / ACCESSWIRE / April 1, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have received a notice of...

Read more

Capstone Therapeutics Announces Operating Results for Fiscal 2020 - Including a Change in Its Deferred Tax Valuation Allowance

March 31, 2021 4:00 PM

ALSIP, IL / ACCESSWIRE / March 31, 2021 / Capstone Therapeutics (OTCQB:CAPS) ("the Company") today filed its Annual Report for the year ended December 31, 2020 with the OTCQB at www.OTCIQ.com. Net income attributable to Capstone Therapeutics Corp. stockholders totaled $8.5 million or $107.59 per share. Net income attributable to Capstone Therapeutics Corp. stockholders included a Federal income tax benefit of $8.7 million or $109.48...

Read more

The Cannabis Science Inc., Share Exchange is Underway! OMNICANNA Files Name Change to Thermic Science International Corporation and Files SPAC Share Structure to Bring Cannabis Science and Recent Acquisition Companies to Begin Trading for All Thermic/ENDO Shareholders!

March 31, 2021 3:00 PM

NASHVILLE, TN / ACCESSWIRE / March 31, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097, OTC ENDO), is pleased to announce the company has successfully completed its name change to Thermic Science International Corporation. The company is equally proud to announce that the new share class has been created for the Cannabis Science share exchange...

Read more

BioLargo 2020 Annual Report Highlights Expanding Commercial Traction for its Cleantech Technologies, Record Revenue Growth and Improved Balance Sheet

March 31, 2021 8:30 AM

WESTMINSTER, CA / ACCESSWIRE / March 31, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable cleantech technologies and full-service environmental engineering company, filed its Annual Report on Form 10-K with the SEC today for the year ended December 31, 2020 (www.biolargo.com/sec-filings). The company has provided highlights from the Annual Report along with commentary on the recent advancements in its mission to "make life...

Read more

Nascent Biotech Announces Initial Dosing Underway in Phase 1 Human Trial for Primary and Metastatic Brain Cancer

March 31, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 31, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech," "Nascent," or the "Company"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies targeting treatment of various cancers and viral infections, is pleased to announce that patients have been enrolled and initial dosing has begun in the Company's landmark Phase I trial to...

Read more

Dyadic Reports 2020 Year End Results and Recent Company Progress

March 30, 2021 4:00 PM

Advancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial To validate C1 produced proteins are safe in humans and accelerate C1 adoption and commercializationTo serve as proof of concept for next-generation multivalent COVID-19 vaccine candidatesExpanded Korea and Southeast Asia vaccine development partnership with Medytox (086900) (KOSDAQ) focused on next-generation COVID-19...

Read more

Bio Lab Naturals, Inc., a Delaware Corporation (BLAB: OTC) Announces Entry into a Lease/Purchase Agreement.

March 30, 2021 4:00 PM

DENVER, CO / ACCESSWIRE / March 30, 2021 / Bio Lab Naturals, Inc., a Delaware corporation, "BLAB" (OTCQB:BLAB), based in Denver, Colorado, desires to provide information to its investors and shareholders related to a Lease/Purchase Agreement dated March 24, 2021. On March 24, 2021, BLAB, through its subsidiary, Prime Time Live, Inc. ("PTL"), entered into a Lease/Purchase Agreement (the "Agreement") with an...

Read more

Pieris Pharmaceuticals Reports Full-Year 2020 Financial Results and Provides Corporate Update

March 30, 2021 7:00 AM

Company To Host an Investor Conference Call on Tuesday, March 30, 2021 at 8:00 AM EDT Pieris achieves $13 million milestone from AstraZeneca for initiation of PRS-060/AZD1402 phase 2a study and AstraZeneca to purchase $10 million equity stake in Pieris common stock as part of an amended collaboration agreement $13 million equity investment by Seagen in Pieris, in addition to a clinical trial and supply agreement to evaluate cinrebafusp...

Read more

ANGLE PLC Announces Global Launch of Clinical Services Laboratories

March 30, 2021 2:00 AM

Delivering on strategy to accelerate commercialisation of the Parsortix system and act as a demonstrator to support product deployment UK and US clinical laboratories now open and ready to provide CTC analysis services and discussions with pharmaceutical industry customers ongoing GUILDFORD, SURREY / ACCESSWIRE / March 30, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that it has...

Read more

Health Canada Provides Positive Feedback on Tetra Bio-Pharma’s Application for ARDS-003 to be Studied in COVID-19 Patients at Risk of Developing Acute Respiratory Distress Syndrome

March 30, 2021 2:00 AM

Health Canada acknowledges that the preclinical safety data are robust and sufficient to file a Clinical Trial Application aimed at treating hospitalized COVID-19 patients at risk of developing ARDS ARDS is the leading cause of mortality in patients with COVID-19 and develops in 20-67% of critically ill patients diagnosed with COVID-19 There is currently no standard, approved treatment for ARDS rendering the indication a significant unmet...

Read more

Experion Holdings Reports Financial Results for the Fourth Quarter and Fiscal Year Ended November 30, 2020

March 29, 2021 4:15 PM

VANCOUVER, BC / ACCESSWIRE / March 29, 2021 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31), Canada's solution to craft cannabis supply and builder of premium cannabis brands including its sought after and popular brand Citizen Stash is pleased to report its fourth quarter and fiscal year end financial results for the period ended November 30, 2020. "The fiscal year...

Read more

Applied UV to Host Full Year 2020 Conference Call on March 31st

March 29, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / March 29, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will host an investor conference...

Read more

Xenetic Biosciences, Inc. Receives Approval to Commence Exploratory Study of XCART(TM)

March 29, 2021 8:05 AM

- Data from the study to provide valuable insights as the Company advances XCART lead program in Non-Hodgkin lymphoma (NHL) towards Investigational New Drug (IND) filing in the United States - Study will evaluate the XCART process of neoantigen identification and generation of tumor-specific CAR T candidates, in a real-world clinical setting FRAMINGHAM, MA / ACCESSWIRE / March 29, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO)...

Read more